Two Firms Fight FDA Exclusivity Battles In US
Alvogen And Sandoz Challenge Buprenorphine, Aubagio Awards
Executive Summary
Alvogen contends Teva forfeited 180-day exclusivity with its settlement, while Sandoz claims Sanofi’s MS drug Aubagio isn’t an NCE because it is an active metabolite.